S&P 500   4,266.58 (-0.17%)
DOW   33,512.12 (-0.15%)
QQQ   353.38 (-0.43%)
AAPL   177.98 (-0.89%)
MSFT   333.50 (-0.73%)
META   271.08 (-0.11%)
GOOGL   126.05 (+0.03%)
AMZN   125.42 (+0.10%)
TSLA   215.04 (-1.18%)
NVDA   387.36 (-1.11%)
NIO   7.62 (-0.65%)
BABA   83.78 (-0.73%)
AMD   118.47 (+0.46%)
T   15.41 (+0.13%)
F   12.58 (-0.08%)
MU   66.93 (-1.24%)
CGC   0.75 (-4.13%)
GE   104.60 (+0.48%)
DIS   91.20 (+0.22%)
AMC   4.55 (-1.73%)
PFE   38.58 (-0.18%)
PYPL   64.38 (-0.20%)
NFLX   399.78 (-0.93%)
S&P 500   4,266.58 (-0.17%)
DOW   33,512.12 (-0.15%)
QQQ   353.38 (-0.43%)
AAPL   177.98 (-0.89%)
MSFT   333.50 (-0.73%)
META   271.08 (-0.11%)
GOOGL   126.05 (+0.03%)
AMZN   125.42 (+0.10%)
TSLA   215.04 (-1.18%)
NVDA   387.36 (-1.11%)
NIO   7.62 (-0.65%)
BABA   83.78 (-0.73%)
AMD   118.47 (+0.46%)
T   15.41 (+0.13%)
F   12.58 (-0.08%)
MU   66.93 (-1.24%)
CGC   0.75 (-4.13%)
GE   104.60 (+0.48%)
DIS   91.20 (+0.22%)
AMC   4.55 (-1.73%)
PFE   38.58 (-0.18%)
PYPL   64.38 (-0.20%)
NFLX   399.78 (-0.93%)
S&P 500   4,266.58 (-0.17%)
DOW   33,512.12 (-0.15%)
QQQ   353.38 (-0.43%)
AAPL   177.98 (-0.89%)
MSFT   333.50 (-0.73%)
META   271.08 (-0.11%)
GOOGL   126.05 (+0.03%)
AMZN   125.42 (+0.10%)
TSLA   215.04 (-1.18%)
NVDA   387.36 (-1.11%)
NIO   7.62 (-0.65%)
BABA   83.78 (-0.73%)
AMD   118.47 (+0.46%)
T   15.41 (+0.13%)
F   12.58 (-0.08%)
MU   66.93 (-1.24%)
CGC   0.75 (-4.13%)
GE   104.60 (+0.48%)
DIS   91.20 (+0.22%)
AMC   4.55 (-1.73%)
PFE   38.58 (-0.18%)
PYPL   64.38 (-0.20%)
NFLX   399.78 (-0.93%)
S&P 500   4,266.58 (-0.17%)
DOW   33,512.12 (-0.15%)
QQQ   353.38 (-0.43%)
AAPL   177.98 (-0.89%)
MSFT   333.50 (-0.73%)
META   271.08 (-0.11%)
GOOGL   126.05 (+0.03%)
AMZN   125.42 (+0.10%)
TSLA   215.04 (-1.18%)
NVDA   387.36 (-1.11%)
NIO   7.62 (-0.65%)
BABA   83.78 (-0.73%)
AMD   118.47 (+0.46%)
T   15.41 (+0.13%)
F   12.58 (-0.08%)
MU   66.93 (-1.24%)
CGC   0.75 (-4.13%)
GE   104.60 (+0.48%)
DIS   91.20 (+0.22%)
AMC   4.55 (-1.73%)
PFE   38.58 (-0.18%)
PYPL   64.38 (-0.20%)
NFLX   399.78 (-0.93%)
NASDAQ:VTRS

Viatris (VTRS) Price Target & Analyst Ratings

$9.38
+0.05 (+0.54%)
(As of 09:34 AM ET)
Compare
Today's Range
$9.32
▼
$9.40
50-Day Range
$9.02
▼
$9.92
52-Week Range
$8.42
▼
$12.40
Volume
141,151 shs
Average Volume
9.36 million shs
Market Capitalization
$11.25 billion
P/E Ratio
5.97
Dividend Yield
5.12%
Price Target
$12.67
ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Viatris Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 7 Analyst Ratings

Consensus Analyst Price Target

$12.67
35.04% Upside
High Prediction$15.00
Average Prediction$12.67
Low Prediction$10.00
TypeCurrent
6/6/22 to 6/6/23		1 Month Ago
5/7/22 to 5/7/23		3 Months Ago
3/8/22 to 3/8/23		1 Year Ago
6/6/21 to 6/6/22
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
1 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
0 Buy rating(s)
Hold
6 Hold rating(s)
6 Hold rating(s)
6 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$12.67$12.67$13.14$13.25
Predicted Upside35.04% Upside14.61% Upside17.74% Upside24.41% Upside
Get Viatris Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for VTRS and its competitors with MarketBeat's FREE daily newsletter.


VTRS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

VTRS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Viatris Stock vs. The Competition

TypeViatrisMedical CompaniesS&P 500
Consensus Rating Score
2.14
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside35.76% Upside1,271.33% Upside219.76% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Historical Target Prices and Ratings

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/24/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOverweight ➝ Equal Weight$11.00+13.99%
2/17/2023BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeOutperform ➝ Market Perform$16.00 ➝ $14.00+20.17%
1/27/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeHold ➝ Buy$13.00 ➝ $15.00+28.87%
11/15/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetNeutral$13.00 ➝ $14.00+21.00%
11/9/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeSell ➝ Neutral$9.00 ➝ $12.00+10.80%
11/8/2022Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 UpgradeUnderweight ➝ Neutral$10.00-8.84%
11/7/2022Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 DowngradeBuy ➝ Neutral
(Data available from 6/6/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












VTRS Price Target - Frequently Asked Questions

What is Viatris's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Viatris stock is Hold based on the current 6 hold ratings and 1 buy rating for VTRS. The average twelve-month price prediction for Viatris is $12.67 with a high price target of $15.00 and a low price target of $10.00. Learn more on VTRS's analyst rating history.

Do Wall Street analysts like Viatris more than its competitors?

Analysts like Viatris less than other Medical companies. The consensus rating for Viatris is Hold while the average consensus rating for medical companies is Buy. Learn more on how VTRS compares to other companies.

Is Viatris being downgraded by Wall Street analysts?

Over the previous 90 days, Viatris's stock had 1 downgrade by analysts.

Does Viatris's stock price have much upside?

According to analysts, Viatris's stock has a predicted upside of 14.61% based on their 12-month price targets.

What analysts cover Viatris?

Viatris has been rated by Barclays in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:VTRS) was last updated on 6/6/2023 by MarketBeat.com Staff

My Account -